128 results on '"Ferrarini, Marina"'
Search Results
2. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators
- Author
-
Vergani, Elisabetta, Dugo, Matteo, Cossa, Mara, Frigerio, Simona, Di Guardo, Lorenza, Gallino, Gianfrancesco, Mattavelli, Ilaria, Vergani, Barbara, Lalli, Luca, Tamborini, Elena, Valeri, Barbara, Gargiuli, Chiara, Shahaj, Eriomina, Ferrarini, Marina, Ferrero, Elisabetta, Gomez Lira, Macarena, Huber, Veronica, Del Vecchio, Michele, Sensi, Marialuisa, Leone, Biagio Eugenio, Santinami, Mario, Rivoltini, Licia, Rodolfo, Monica, and Vallacchi, Viviana
- Published
- 2020
- Full Text
- View/download PDF
3. Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production
- Author
-
Cantoni, Eleonora, primary, Merelli, Ivan, additional, Stefanoni, Davide, additional, Tomelleri, Alessandro, additional, Campochiaro, Corrado, additional, Giordano, Vito, additional, Panigada, Maddalena, additional, Baldissera, Elena M, additional, Merlo Pich, Laura, additional, Natoli, Valentina, additional, Ziogas, Athanasios, additional, Domínguez-Andrés, Jorge, additional, De Luca, Giacomo, additional, Mazza, Davide, additional, Zambrano, Samuel, additional, Gnani, Daniela, additional, Ferrarini, Marina, additional, Ferrero, Elisabetta, additional, Agresti, Alessandra, additional, Vergani, Barbara, additional, Leone, Biagio Eugenio, additional, Cenci, Simone, additional, Ravelli, Angelo, additional, Matucci-Cerinic, Marco, additional, D’Alessandro, Angelo, additional, Joosten, Leo A B, additional, Dagna, Lorenzo, additional, Netea, Mihai G, additional, Molteni, Raffaella, additional, and Cavalli, Giulio, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production
- Author
-
Cantoni, E, Merelli, I, Stefanoni, D, Tomelleri, A, Campochiaro, C, Giordano, V, Panigada, M, Baldissera, E, Merlo Pich, L, Natoli, V, Ziogas, A, Domínguez-Andrés, J, De Luca, G, Mazza, D, Zambrano, S, Gnani, D, Ferrarini, M, Ferrero, E, Agresti, A, Vergani, B, Leone, B, Cenci, S, Ravelli, A, Matucci-Cerinic, M, D'Alessandro, A, Joosten, L, Dagna, L, Netea, M, Molteni, R, Cavalli, G, Cantoni, Eleonora, Merelli, Ivan, Stefanoni, Davide, Tomelleri, Alessandro, Campochiaro, Corrado, Giordano, Vito, Panigada, Maddalena, Baldissera, Elena M, Merlo Pich, Laura, Natoli, Valentina, Ziogas, Athanasios, Domínguez-Andrés, Jorge, De Luca, Giacomo, Mazza, Davide, Zambrano, Samuel, Gnani, Daniela, Ferrarini, Marina, Ferrero, Elisabetta, Agresti, Alessandra, Vergani, Barbara, Leone, Biagio Eugenio, Cenci, Simone, Ravelli, Angelo, Matucci-Cerinic, Marco, D'Alessandro, Angelo, Joosten, Leo A B, Dagna, Lorenzo, Netea, Mihai G, Molteni, Raffaella, Cavalli, Giulio, Cantoni, E, Merelli, I, Stefanoni, D, Tomelleri, A, Campochiaro, C, Giordano, V, Panigada, M, Baldissera, E, Merlo Pich, L, Natoli, V, Ziogas, A, Domínguez-Andrés, J, De Luca, G, Mazza, D, Zambrano, S, Gnani, D, Ferrarini, M, Ferrero, E, Agresti, A, Vergani, B, Leone, B, Cenci, S, Ravelli, A, Matucci-Cerinic, M, D'Alessandro, A, Joosten, L, Dagna, L, Netea, M, Molteni, R, Cavalli, G, Cantoni, Eleonora, Merelli, Ivan, Stefanoni, Davide, Tomelleri, Alessandro, Campochiaro, Corrado, Giordano, Vito, Panigada, Maddalena, Baldissera, Elena M, Merlo Pich, Laura, Natoli, Valentina, Ziogas, Athanasios, Domínguez-Andrés, Jorge, De Luca, Giacomo, Mazza, Davide, Zambrano, Samuel, Gnani, Daniela, Ferrarini, Marina, Ferrero, Elisabetta, Agresti, Alessandra, Vergani, Barbara, Leone, Biagio Eugenio, Cenci, Simone, Ravelli, Angelo, Matucci-Cerinic, Marco, D'Alessandro, Angelo, Joosten, Leo A B, Dagna, Lorenzo, Netea, Mihai G, Molteni, Raffaella, and Cavalli, Giulio
- Abstract
Objective: Trained immunity (TI) is a de facto memory program of innate immune cells, characterized by immunometabolic and epigenetic changes sustaining enhanced production of cytokines. TI evolved as a protective mechanism against infections; however, inappropriate activation can cause detrimental inflammation and might be implicated in the pathogenesis of chronic inflammatory diseases. In this study, we investigated the role of TI in the pathogenesis of giant cell arteritis (GCA), a large-vessel vasculitis characterized by aberrant macrophage activation and excess cytokine production. Methods: Monocytes from GCA patients and from age- and sex-matched healthy donors were subjected to polyfunctional studies, including cytokine production assays at baseline and following stimulation, intracellular metabolomics, chromatin immunoprecipitation-qPCR, and combined ATAC/RNA sequencing. Immunometabolic activation (i.e. glycolysis) was assessed in inflamed vessels of GCA patients with FDG-PET and immunohistochemistry (IHC), and the role of this pathway in sustaining cytokine production was confirmed with selective pharmacologic inhibition in GCA monocytes. Results: GCA monocytes exhibited hallmark molecular features of TI. Specifically, these included enhanced IL-6 production upon stimulation, typical immunometabolic changes (e.g. increased glycolysis and glutaminolysis) and epigenetic changes promoting enhanced transcription of genes governing pro-inflammatory activation. Immunometabolic changes of TI (i.e. glycolysis) were a feature of myelomonocytic cells in GCA lesions and were required for enhanced cytokine production. Conclusions: Myelomonocytic cells in GCA activate TI programs sustaining enhanced inflammatory activation with excess cytokine production.
- Published
- 2023
5. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment
- Author
-
Valsecchi, Roberta, Coltella, Nadia, Belloni, Daniela, Ponente, Manfredi, ten Hacken, Elisa, Scielzo, Cristina, Scarfò, Lydia, Bertilaccio, Maria Teresa Sabrina, Brambilla, Paola, Lenti, Elisa, Martinelli Boneschi, Filippo, Brendolan, Andrea, Ferrero, Elisabetta, Ferrarini, Marina, Ghia, Paolo, Tonon, Giovanni, Ponzoni, Maurilio, Caligaris-Cappio, Federico, and Bernardi, Rosa
- Published
- 2016
- Full Text
- View/download PDF
6. Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system
- Author
-
Belloni, Daniela, primary, Ferrarini, Marina, additional, Ferrero, Elisabetta, additional, Guzzeloni, Virginia, additional, Barbaglio, Federica, additional, Ghia, Paolo, additional, and Scielzo, Cristina, additional
- Published
- 2022
- Full Text
- View/download PDF
7. 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations
- Author
-
Guzzeloni, Virginia, primary, Veschini, Lorenzo, additional, Pedica, Federica, additional, Ferrero, Elisabetta, additional, and Ferrarini, Marina, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis
- Author
-
Ferrero, Elisabetta, primary, Villa, Antonello, additional, Stefanoni, Davide, additional, Nemkov, Travis, additional, D’Alessandro, Angelo, additional, Tengesdal, Isak, additional, Belloni, Daniela, additional, Molteni, Raffaella, additional, Vergani, Barbara, additional, De Luca, Giacomo, additional, Grassini, Greta, additional, Cangi, Maria Giulia, additional, Dagna, Lorenzo, additional, Doglioni, Claudio, additional, Cavalli, Giulio, additional, and Ferrarini, Marina, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease
- Author
-
Biavasco, Riccardo, primary, Molteni, Raffaella, additional, Stefanoni, Davide, additional, Nemkov, Travis, additional, Netea, Mihai G., additional, Domínguez-Andrés, Jorge, additional, Arts, Rob JW, additional, Merelli, Ivan, additional, Mazza, Davide, additional, Zambrano, Samuel, additional, Panigada, Maddalena, additional, Cantoni, Eleonora, additional, Tengesdal, Isak, additional, Maksud, Philippe, additional, Piras, Francesco, additional, De Luca, Giacomo, additional, Cassina, Laura, additional, Distefano, Gianfranco, additional, Loffreda, Alessia, additional, Gnani, Daniela, additional, Doglioni, Claudio, additional, Tomelleri, Alessandro, additional, Campochiaro, Corrado, additional, Joosten, Leo, additional, Dinarello, Charles A, additional, Kajaste-Rudnitski, Anna, additional, Haroche, Julien, additional, Cardaci, Simone, additional, Cenci, Simone, additional, Dagna, Lorenzo, additional, Ferrarini, Marina, additional, Ferrero, Elisabetta, additional, Boletta, Alessandra, additional, D'Alessandro, Angelo, additional, Montini, Eugenio, additional, and Cavalli, Giulio, additional
- Published
- 2021
- Full Text
- View/download PDF
10. Constitutive expression of IL-12Rβ2 on human multiple myeloma cells delineates a novel therapeutic target
- Author
-
Airoldi, Irma, Cocco, Claudia, Giuliani, Nicola, Ferrarini, Marina, Colla, Simona, Ognio, Emanuela, Taverniti, Giuseppe, Di Carlo, Emma, Cutrona, Giovanna, Perfetti, Vittorio, Rizzoli, Vittorio, Ribatti, Domenico, and Pistoia, Vito
- Published
- 2008
- Full Text
- View/download PDF
11. TNF-α in Erdheim–Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab
- Author
-
Ferrero, Elisabetta, Belloni, Daniela, Corti, Angelo, Doglioni, Claudio, Dagna, Lorenzo, and Ferrarini, Marina
- Published
- 2014
- Full Text
- View/download PDF
12. Additional file 3 of miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators
- Author
-
Vergani, Elisabetta, Dugo, Matteo, Cossa, Mara, Frigerio, Simona, Di Guardo, Lorenza, Gallino, Gianfrancesco, Mattavelli, Ilaria, Vergani, Barbara, Lalli, Luca, Tamborini, Elena, Valeri, Barbara, Gargiuli, Chiara, Shahaj, Eriomina, Ferrarini, Marina, Ferrero, Elisabetta, Gomez Lira, Macarena, Huber, Veronica, Del Vecchio, Michele, Sensi, Marialuisa, Leone, Biagio Eugenio, Santinami, Mario, Rivoltini, Licia, Rodolfo, Monica, and Vallacchi, Viviana
- Abstract
Additional file 2: Supplementary Fig. S1. Altered miR-146a expression influences BRAF/MEKi sensitivity and apoptosis in melanoma. A) Boxplots representing IC50 values of 6 matched PLX4032-resistant (R) and sensitive (S) melanoma cell lines to PLX4032 (vemurafenib), BRAFi (dabrafenib), MEKi (trametinib), to the combined treatment BRAF/MEKi, and to sTRAIL-induced apoptosis. B) Inverse correlation between miR-146a expression levels and IC50 values of PLX4032, BRAFi and MEKi in melanoma cell lines (Spearman analysis). C) Forced expression of miR-146a (+m-miR-146a) in LM16R cell line and in LM69 and LM70 short term cultures increased the effects of PLX4032 treatment as shown by reduced cell growth and increased cell cytotoxicity and apoptosis, evaluated by CCK8, LDH and caspase 8 and 3/7 activity. D) Inhibition of miR-146a expression (i-miR-146a) in LM16 cells increased cell proliferation and decreased the release of LDH and the apoptosis rate as evaluated by CCK8, LDH and caspase 3/7 activity. E) Overexpression of miR-146a (m-miR-146a) upon PLX4032, BRAF/MEKi and sTRAIL treatments in LM47R cells increased cell cytotoxicity and apoptosis, as evaluated by LDH and caspase 8 and 3/7 activity. Data are plotted compared to scrambled control. *: p < 0.05, **: p < 0.01, ***: p < 0.0001 by Student’s unpaired t test. Supplementary Fig. S2. COX2 inhibition increases sensitivity to PLX4032 and to BRAF/MEKi and reduces PGE2 release. A) Relative luciferase activity after co-transfection of PTGS2 3’UTR luciferase reporter vector or control vector with miR-146a mimic or mimic negative control. Experiment was performed in LM16R cells. B) Inverse correlation between miR-146a expression levels and IC50 values of PLX4032 in melanoma cell lines (Spearman analysis). C) Western blot analyses showing downregulation of COX2 after transfection with siRNA against COX2 (siCOX2) compared to scrambled control (S). COX2 protein levels were downregulated to 15%, as determined by quantification of the signal and expressed as the ratio of COX2/Actin intensity. Experiment was performed with LM47R cells. D) Silencing of COX2 by siRNA transfection enhanced cell growth inhibition and increased cell cytotoxicity and apoptosis upon treatment with PLX4032 compared to scrambled control. E) PGE2 release in culture supernatants following 24 h treatment with the COX2 inhibitors celecoxib and NS398, alone or in combination with BRAF/MEKi. F) Combined treatment with celecoxib increased cell growth inhibition and cytotoxicity by PLX4032. ●: interaction index = 1. G) Dose-dependent effect of celecoxib alone (5, 10, 20, 40, 50 and 80 μM) and combined with PLX4032 (3 μM) on cell growth. ●: interaction index = 1 at the dose of 50 μM of celecoxib combined with PLX4032. P values were calculated by Student’s unpaired t test in A, D and F, by one-way ANOVA followed by Bonferroni correction in E, and by two-way ANOVA followed by Bonferroni correction in G. *: p < 0.05, **: p < 0.01, ***: p < 0.0001. Supplementary Fig. S3. miR-146a expression levels are inversely correlated with levels of target genes. Analysis of correlation between miR-146a expression and its target genes EGFR, CCL2 and BCL2L1 in metastatic melanoma specimens. The rp and p values resulting from Pearson analysis are shown. Supplementary Fig. S4. Dynamic culture in bioreactor preserves TME architecture of 3D tumor explants. Representative histological images of H&E-stained 3D tumor sections after 3 days culture in bioreactor. The marked areas in the left panels are shown at higher magnification in the right panels to display the preserved cellularity and tumor tissue histo-architecture. Scale bar 80 μM. Supplementary Fig. S5. miR-146a overexpression increases drug sensitivity in 3D cultures of tumor explants. A) Modulation of direct and indirect miR-146a target genes upon transfection of miR-146a mimic (m-miR-146a) compared to scrambled-transfected control (S) in 3D cultures of BRAF-mutated melanoma tumors from naïve patients. AU: arbitrary units. B) Decreased staining for Ki67 and pERK proliferating cells and increased Caspase 3 positive cells in 3D cultures upon treatment with BRAF/MEKi and transfection with miR-146a (m-miR-146a) or scrambled control (S). Scale bar 10 um.
- Published
- 2020
- Full Text
- View/download PDF
13. Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis.
- Author
-
Ferrero, Elisabetta, Villa, Antonello, Stefanoni, Davide, Nemkov, Travis, D'Alessandro, Angelo, Tengesdal, Isak, Belloni, Daniela, Molteni, Raffaella, Vergani, Barbara, Luca, Giacomo De, Grassini, Greta, Cangi, Maria Giulia, Dagna, Lorenzo, Doglioni, Claudio, Cavalli, Giulio, and Ferrarini, Marina
- Subjects
CYTOKINES ,GENETIC mutation ,SKIN ,PROTEIN kinase inhibitors ,IMMUNOHISTOCHEMISTRY ,MACROPHAGES ,LANGERHANS-cell histiocytosis ,GENE expression ,CELLULAR signal transduction ,CYTOKINE release syndrome ,PHOSPHORYLATION - Abstract
The article presents a case study which characterized the functional and metabolic outcomes of an activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation in a patient affected by Langerhans-related histiocytosis. Topics include case of a patient with articular, pituitary and skin involvement, comparison between the supernatant of tissue lesions and tissue culture medium, and clinical effectiveness MAPK pathway inhibition with selective MEK inhibitors in histiocytosis patients.
- Published
- 2022
- Full Text
- View/download PDF
14. Erdheim-Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancer
- Author
-
Cavalli, Giulio, primary, Dagna, Lorenzo, additional, Biavasco, Riccardo, additional, Villa, Antonello, additional, Doglioni, Claudio, additional, Ferrero, Elisabetta, additional, and Ferrarini, Marina, additional
- Published
- 2020
- Full Text
- View/download PDF
15. Erdheim–Chester disease: report on a case and new insights on its immunopathogenesis
- Author
-
Dagna, Lorenzo, Girlanda, Stefania, Langheim, Silvia, Rizzo, Nathalie, Bozzolo, Enrica Paola, Sabbadini, Maria Grazia, and Ferrarini, Marina
- Published
- 2010
- Full Text
- View/download PDF
16. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: Implications for pathogenesis
- Author
-
Stoppacciaro, Antonella, Ferrarini, Marina, Salmaggi, Chiara, Colarossi, Cristina, Praderio, Luisa, Tresoldi, Moreno, Beretta, Angelo A., and Sabbadini, Maria Grazia
- Published
- 2006
17. Macrophages exposed to Mycobacterium tuberculosis release chemokines able to recruit selected leucocyte subpopulations: focus on γδ cells
- Author
-
FERRERO, ELISABETTA, BISWAS, PRISCILLA, VETTORETTO, KATUSCIA, FERRARINI, MARINA, UGUCCIONI, MARIAGRAZIA, PIALI, LUCA, LEONE, BIAGIO EUGENIO, MOSER, BERNHARD, RUGARLI, CLAUDIO, and PARDI, RUGGERO
- Published
- 2003
18. Killing of laminin receptor-positive human lung cancers by tumor-infiltrating lymphocytes bearing gamma-delta+ T-cell receptors
- Author
-
Ferrarini, Marina, Heltai, Silvia, Pupa, Serenella M., Menard, Sylvie, and Zocchi, M. Raffaella
- Subjects
T cells -- Receptors ,Lung cancer ,Tumor-infiltrating lymphocytes -- Health aspects ,Health - Abstract
Background. The monomeric laminin receptor, a 67-kd high-affinity laminin-binding protein, is expressed by a variety of normal cell types. Overexpression and abnormal surface distribution of this receptor have been demonstrated in tumor cells, where it appears to promote tumor invasion and metastasis. Previously, we reported the existence of an association between laminin receptor overexpression by lung c-ancer cells and the presence of tumor-infiltrating lymphocytes (TILs) bearing [gamma][zeta] T-cell receptors. [gamma][zeta]+ lymphocytes represent a sizable fraction of the TILs in approximately one fourth of lung cancers analyzed thus far. Purpose: The aim of this study was to determine whether [gamma][zeta]+ TILs might participate in the immune response against lung cancer through recognition of monomeric laminin receptors expressed by tumor cells. Methods: Tumor cells from 11 lung cancer specimens exhibiting sizable [gamma][zeta]+ T-cell infiltrates and from 11 other specimens infiltrated predominantly by lymphocytes bearing [alpha][beta] T-cell receptors were analyzed for expression of the monomeric laminin receptor by use of the monoclonal antibody (MAb) MLuC5. [gamma][zeta]+ TILs and [alpha][beta]+ TILs derived from four tumors were each examined for cytotoxic activity toward lung cancer target cells by use of a standard 51Cr-release assay and lung tumor cell lines expressing different levels of surface monomeric laminin receptor. The ability of MAbs directed against the laminin receptor (i.e., MLUC5) or against [gamma][zeta] T-cell receptors (i.e., Ti[gamma]A and A13) as well as laminin peptides known to bind to the laminin receptor to inhibit TIL-mediated target cell lysis was also determined. Results: We confirmed that the association between overexpression of the monomeric laminin receptor by lung tumor cells and the presence of [gamma][zeta]+ TILs is statistically significant (two-sided P = .003; Fisher's exact test). We also observed a relationship between the levels of laminin receptor expression on cultured lung cancer cells and their susceptibility to specific lysis by [gamma][zeta]+, but not [alpha][beta]+, TILs. This specific cell killing was not T-cell receptor mediated, but it was inhibited by addition of the anti-monomeric laminin receptor MAb MLUC5 and by a synthetic peptide corresponding to amino acids 2091-2108 of the laminin A chain. Conclusions and Implications: Our results indicate that [gamma][zeta]+ TILs localized at human lung cancer sites can kill tumor cells in a process that involves interaction with the monomeric laminin receptor. The infiltration of [gamma][zeta]+ TILs at lung tumor sites may represent a first line of defense against cells undergoing malignant transformation. [J Natl Cancer Inst 1996;88:436-411
- Published
- 1996
19. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3d surrogate microenvironment
- Author
-
Belloni, D, Heltai, S, Ponzoni, M, Villa, A, Vergani, B, Pecciarini, L, Marcatti, M, Girlanda, S, Tonon, G, Ciceri, F, Caligaris-Cappio, F, Ferrarini, M, Ferrero, E, Belloni, Daniela, Heltai, Silvia, Ponzoni, Maurilio, Villa, Antonello, Vergani, Barbara, Pecciarini, Lorenza, Marcatti, Magda, Girlanda, Stefania, Tonon, Giovanni, Ciceri, Fabio, Caligaris-Cappio, Federico, Ferrarini, Marina, Ferrero, Elisabetta, Belloni, D, Heltai, S, Ponzoni, M, Villa, A, Vergani, B, Pecciarini, L, Marcatti, M, Girlanda, S, Tonon, G, Ciceri, F, Caligaris-Cappio, F, Ferrarini, M, Ferrero, E, Belloni, Daniela, Heltai, Silvia, Ponzoni, Maurilio, Villa, Antonello, Vergani, Barbara, Pecciarini, Lorenza, Marcatti, Magda, Girlanda, Stefania, Tonon, Giovanni, Ciceri, Fabio, Caligaris-Cappio, Federico, Ferrarini, Marina, and Ferrero, Elisabetta
- Abstract
Multiple myeloma develops primarily inside the bone marrow microenvironment, that confers pro-survival signals and drug resistance. 3D cultures that reproduce multiple myeloma-bone marrow interactions are needed to fully investigate multiple myeloma pathogenesis and response to drugs. To this purpose, we exploited the 3D Rotary Cell Culture System bioreactor technology for myelomabone marrow co-cultures in gelatin scaffolds. The model was validated with myeloma cell lines that, as assessed by histochemical and electronmicroscopic analyses, engaged contacts with stromal cells and endothelial cells. Consistently, pro-survival signaling and also cell adhesionmediated drug resistance were significantly higher in 3D than in 2D parallel co-cultures. The contribution of the VLA-4/VCAM1 pathway to resistance to bortezomib was modeled by the use of VCAM1 transfectants. Soluble factor-mediated drug resistance could be also demonstrated in both 2D and 3D co-cultures. The system was then successfully applied to co-cultures of primary myeloma cells-primary myeloma bone marrow stromal cells from patients and endothelial cells, allowing the development of functional myeloma-stroma interactions and MM cell long-term survival. Significantly, genomic analysis performed in a highrisk myeloma patient demonstrated that culture in bioreactor paralleled the expansion of the clone that ultimately dominated in vivo. Finally, the impact of bortezomib on myeloma cells and on specialized functions of the microenvironment could be evaluated. Our findings indicate that 3D dynamic culture of reconstructed human multiple myeloma microenvironments in bioreactor may represent a useful platform for drug testing and for studying tumor-stroma molecular interactions.
- Published
- 2018
20. Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease
- Author
-
Molteni, Raffaella, Biavasco, Riccardo, Stefanoni, Davide, Nemkov, Travis, Domínguez-Andrés, Jorge, Arts, Rob J., Merelli, Ivan, Mazza, Davide, Zambrano, Samuel, Panigada, Maddalena, Cantoni, Eleonora, Tengesdal, Isak W., Maksud, Philippe, Piras, Francesco, Cesana, Daniela, Cassina, Laura, Distefano, Gianfranco, Loffreda, Alessia, Gnani, Daniela, De Luca, Giacomo, Tomelleri, Alessandro, Campochiaro, Corrado, Joosten, Leo A.B., Dinarello, Charles A., Kajaste-Rudnitski, Anna, Haroche, Julien, Cardaci, Simone, Cenci, Simone, Dagna, Lorenzo, Doglioni, Claudio, Ferrarini, Marina, Ferrero, Elisabetta, Boletta, Alessandra, D'Alessandro, Angelo, Montini, Eugenio, Netea, Mihai G., and Cavalli, Giulio
- Abstract
Trained immunity (TI) is a proinflammatory program induced in monocyte/macrophages upon sensing of specific pathogens and is characterized by immunometabolic and epigenetic changes that enhance cytokine production. Maladaptive activation of TI (ie, in the absence of infection) may result in detrimental inflammation and development of disease; however, the exact role and extent of inappropriate activation of TI in the pathogenesis of human diseases is undetermined. In this study, we uncovered the oncogene-induced, maladaptive induction of TI in the pathogenesis of a human inflammatory myeloid neoplasm (Erdheim-Chester disease, [ECD]), characterized by the BRAFV600E oncogenic mutation in monocyte/macrophages and excess cytokine production. Mechanistically, myeloid cells expressing BRAFV600E exhibit all molecular features of TI: activation of the AKT/mammalian target of rapamycin signaling axis; increased glycolysis, glutaminolysis, and cholesterol synthesis; epigenetic changes on promoters of genes encoding cytokines; and enhanced cytokine production leading to hyperinflammatory responses. In patients with ECD, effective therapeutic strategies combat this maladaptive TI phenotype; in addition, pharmacologic inhibition of immunometabolic changes underlying TI (ie, glycolysis) effectively dampens cytokine production by myeloid cells. This study revealed the deleterious potential of inappropriate activation of TI in the pathogenesis of human inflammatory myeloid neoplasms and the opportunity for inhibition of TI in conditions characterized by maladaptive myeloid-driven inflammation.
- Published
- 2021
- Full Text
- View/download PDF
21. The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease
- Author
-
Pacini, Greta, primary, Cavalli, Giulio, additional, Tomelleri, Alessandro, additional, De Luca, Giacomo, additional, Pacini, Guido, additional, Ferrarini, Marina, additional, Doglioni, Claudio, additional, and Dagna, Lorenzo, additional
- Published
- 2018
- Full Text
- View/download PDF
22. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment
- Author
-
Belloni, Daniela, primary, Heltai, Silvia, additional, Ponzoni, Maurilio, additional, Villa, Antonello, additional, Vergani, Barbara, additional, Pecciarini, Lorenza, additional, Marcatti, Magda, additional, Girlanda, Stefania, additional, Tonon, Giovanni, additional, Ciceri, Fabio, additional, Caligaris-Cappio, Federico, additional, Ferrarini, Marina, additional, and Ferrero, Elisabetta, additional
- Published
- 2018
- Full Text
- View/download PDF
23. Tocilizumab in patients with multisystem Erdheim–Chester disease
- Author
-
Berti, Alvise, primary, Cavalli, Giulio, additional, Guglielmi, Barbara, additional, Biavasco, Riccardo, additional, Campochiaro, Corrado, additional, Tomelleri, Alessandro, additional, Nicoletti, Roberto, additional, Panzacchi, Andrea, additional, Ferrarini, Marina, additional, and Dagna, Lorenzo, additional
- Published
- 2017
- Full Text
- View/download PDF
24. Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim–Chester disease
- Author
-
Ferrero, Elisabetta, primary, Corti, Angelo, additional, Haroche, Julien, additional, Belloni, Daniela, additional, Colombo, Barbara, additional, Berti, Alvise, additional, Cavalli, Giulio, additional, Campochiaro, Corrado, additional, Villa, Antonello, additional, Cohen-Aubart, Fleur, additional, Amoura, Zahir, additional, Doglioni, Claudio, additional, Dagna, Lorenzo, additional, and Ferrarini, Marina, additional
- Published
- 2016
- Full Text
- View/download PDF
25. Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients
- Author
-
Bianco, Mimma, primary, Gasparri, Anna Maria, additional, Colombo, Barbara, additional, Curnis, Flavio, additional, Girlanda, Stefania, additional, Ponzoni, Maurilio, additional, Bertilaccio, Maria Teresa Sabrina, additional, Calcinotto, Arianna, additional, Sacchi, Angelina, additional, Ferrero, Elisabetta, additional, Ferrarini, Marina, additional, Chesi, Marta, additional, Bergsagel, P. Leif, additional, Bellone, Matteo, additional, Tonon, Giovanni, additional, Ciceri, Fabio, additional, Marcatti, Magda, additional, Caligaris-Cappio, Federico, additional, and Corti, Angelo, additional
- Published
- 2016
- Full Text
- View/download PDF
26. Innovative Models to Assess Multiple Myeloma Biology and the Impact of Drugs
- Author
-
Ferrarini, Marina
- Subjects
Medical / Hematology - Abstract
Innovative Models to Assess Multiple Myeloma Biology and the Impact of Drugs
- Published
- 2013
27. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
- Author
-
Diamond, Eli L., primary, Dagna, Lorenzo, additional, Hyman, David M., additional, Cavalli, Giulio, additional, Janku, Filip, additional, Estrada-Veras, Juvianee, additional, Ferrarini, Marina, additional, Abdel-Wahab, Omar, additional, Heaney, Mark L., additional, Scheel, Paul J., additional, Feeley, Nancy K., additional, Ferrero, Elisabetta, additional, McClain, Kenneth L., additional, Vaglio, Augusto, additional, Colby, Thomas, additional, Arnaud, Laurent, additional, and Haroche, Julien, additional
- Published
- 2014
- Full Text
- View/download PDF
28. Correction: Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCCS™ Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy
- Author
-
Ferrarini, Marina, primary, Steimberg, Nathalie, additional, Ponzoni, Maurilio, additional, Belloni, Daniela, additional, Berenzi, Angiola, additional, Girlanda, Stefania, additional, Caligaris-Cappio, Federico, additional, Mazzoleni, Giovanna, additional, and Ferrero, Elisabetta, additional
- Published
- 2013
- Full Text
- View/download PDF
29. Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCCS™ Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy
- Author
-
Ferrarini, Marina, primary, Steimberg, Nathalie, additional, Ponzoni, Maurilio, additional, Belloni, Daniela, additional, Berenzi, Angiola, additional, Girlanda, Stefania, additional, Caligaris-Cappio, Federico, additional, Mazzoleni, Giovanna, additional, and Ferrero, Elisabetta, additional
- Published
- 2013
- Full Text
- View/download PDF
30. Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas function
- Author
-
Clementi, Rita, Chiocchetti, Annalisa, Cappellano, Giuseppe, Cerutti, Elisa, Ferretti, Massimo, Orilieri, Elisabetta, Dianzani, Irma, Ferrarini, Marina, Bregni, Marco, Danesino, Cesare, Bozzi, Valeria, Putti, Maria Caterina, Cerutti, Franco, Cometa, Angela, Locatelli, Franco, Maccario, Rita, Ramenghi, Ugo, Dianzani, Umberto, Locatelli, Franco (ORCID:0000-0002-7976-3654), Clementi, Rita, Chiocchetti, Annalisa, Cappellano, Giuseppe, Cerutti, Elisa, Ferretti, Massimo, Orilieri, Elisabetta, Dianzani, Irma, Ferrarini, Marina, Bregni, Marco, Danesino, Cesare, Bozzi, Valeria, Putti, Maria Caterina, Cerutti, Franco, Cometa, Angela, Locatelli, Franco, Maccario, Rita, Ramenghi, Ugo, Dianzani, Umberto, and Locatelli, Franco (ORCID:0000-0002-7976-3654)
- Abstract
Mutations decreasing function of the Fas death receptor cause the autoimmune lymphoproliferative syndrome (ALPS) with autoimmune manifestations, spleen/lymph node enlargement, and expansion of CD4/CD8-negative T cells. Dianzani Autoimmune Lymphoproliferative Disease (DALD) is a variant lacking this expansion. Perforin is involved in cell-mediated cytotoxicity and its biallelic mutations cause familial hemophagocytic lympho-histiocytosis (HLH). We previously described an ALPS patient carrying het-erozygous mutations of the Fas and perforin genes and suggested that they concurred in ALPS. This work extends the analysis to 14 ALPS, 28 DALD, and 816 controls, and detects an N252S amino acid substitution in 2 ALPS, and an A91V amino acid substitution in 6 DALD. N252S conferred an OR = 62.7 (P =.0016) for ALPS and A91V conferred an OR = 3 (P =.016) for DALD. Copresence of A91V and variations of the osteopontin gene previously associated with DALD conferred an OR = 17 (P =.0007) for DALD. In one N252S patient, NK activity was strikingly defective in early childhood, but became normal in late childhood. A91V patients displayed lower NK activity than controls. These data suggest that perforin variations are a susceptibility factor for ALPS/DALD development in subjects with defective Fas function and may influence disease expression.
- Published
- 2006
31. Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma
- Author
-
Clementi, Rita, Dagna, Lorenzo, Dianzani, Umberto, Dupré, Loïc, Dianzani, Irma, Ponzoni, Maurilio, Cometa, Angela, Chiocchetti, Annalisa, Sabbadini, Maria Grazia, Rugarli, Claudio, Ciceri, Fabio, Maccario, Rita, Locatelli, Franco, Danesino, Cesare, Ferrarini, Marina, Bregni, Marco, Locatelli, Franco (ORCID:0000-0002-7976-3654), Clementi, Rita, Dagna, Lorenzo, Dianzani, Umberto, Dupré, Loïc, Dianzani, Irma, Ponzoni, Maurilio, Cometa, Angela, Chiocchetti, Annalisa, Sabbadini, Maria Grazia, Rugarli, Claudio, Ciceri, Fabio, Maccario, Rita, Locatelli, Franco, Danesino, Cesare, Ferrarini, Marina, Bregni, Marco, and Locatelli, Franco (ORCID:0000-0002-7976-3654)
- Abstract
27-year-old man with the autoimmune lymphoproliferative syndrome and a large-B-cell lymphoma had heterozygous mutations in the Fas and perforin (Prf1) genes. The Fas mutation was inherited from his healthy father and was also carried by his healthy brother, whereas the Prf1 mutation was inherited from his healthy mother. The combined effect of the two mutant genes may have contributed to the development of the autoimmune lymphoproliferative syndrome and lymphoma in this patient.
- Published
- 2004
32. Hypoxia-inducible transcription factor–1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib
- Author
-
Veschini, Lorenzo, primary, Belloni, Daniela, additional, Foglieni, Chiara, additional, Cangi, Maria Giulia, additional, Ferrarini, Marina, additional, Caligaris-Cappio, Federico, additional, and Ferrero, Elisabetta, additional
- Published
- 2006
- Full Text
- View/download PDF
33. MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-Activated γδ Lymphocytes
- Author
-
Girlanda, Stefania, primary, Fortis, Claudio, additional, Belloni, Daniela, additional, Ferrero, Elisabetta, additional, Ticozzi, Paolo, additional, Sciorati, Clara, additional, Tresoldi, Moreno, additional, Vicari, Aurelio, additional, Spies, Thomas, additional, Groh, Veronika, additional, Caligaris-Cappio, Federico, additional, and Ferrarini, Marina, additional
- Published
- 2005
- Full Text
- View/download PDF
34. Inherited Perforin and Fas Mutations in a Patient with Autoimmune Lymphoproliferative Syndrome and Lymphoma.
- Author
-
Clementi, Rita, primary, Dagna, Lorenzo, primary, Dianzani, Umberto, primary, Dupre, Loic, primary, Dianzani, Irma, primary, Ciceri, Fabio, primary, Maccario, Rita, primary, Locatelli, Franco, primary, Danesino, Cesare, primary, Ferrarini, Marina, primary, and Bregni, Marco, primary
- Published
- 2004
- Full Text
- View/download PDF
35. Macrophages exposed to Mycobacterium tuberculosis release chemokines able to recruit selected leucocyte subpopulations: focus on gammadelta cells
- Author
-
Ferrero, Elisabetta, primary, Biswas, Priscilla, additional, Vettoretto, Katuscia, additional, Ferrarini, Marina, additional, Uguccioni, Mariagrazia, additional, Piali, Luca, additional, Leone, Biagio Eugenio, additional, Moser, Bernhard, additional, Rugarli, Claudio, additional, and Pardi, Ruggero, additional
- Published
- 2003
- Full Text
- View/download PDF
36. Autocrine Nitric Oxide Modulates CD95-induced Apoptosis in γδ T Lymphocytes
- Author
-
Sciorati, Clara, primary, Rovere, Patrizia, additional, Ferrarini, Marina, additional, Heltai, Silvia, additional, Manfredi, Angelo A., additional, and Clementi, Emilio, additional
- Published
- 1997
- Full Text
- View/download PDF
37. Killing of Laminin Receptor-Positive Human Lung Cancers by Tumor-Infiltrating Lymphocytes Bearing γδ + T-Cell Receptors
- Author
-
Ferrarini, Marina, primary, Heltai, Silvia, additional, Pupa, Serenella M., additional, Menard, Sylvie, additional, and Zocchi, M. Raffaella, additional
- Published
- 1996
- Full Text
- View/download PDF
38. Ex-Vivo Dynamic 3-D Culture of Human Tissues in the RCCS™ Bioreactor Allows the Study of Multiple Myeloma Biology and Response to Therapy.
- Author
-
Ferrarini, Marina, Steimberg, Nathalie, Ponzoni, Maurilio, Belloni, Daniela, Berenzi, Angiola, Girlanda, Stefania, Caligaris-Cappio, Federico, Mazzoleni, Giovanna, and Ferrero, Elisabetta
- Subjects
- *
MULTIPLE myeloma treatment , *MEDICAL imaging systems , *THREE-dimensional imaging , *CANCER cells , *CANCER chemotherapy , *DRUG development , *CELL-mediated cytotoxicity , *VASCULAR endothelial growth factors - Abstract
Three-dimensional (3-D) culture models are emerging as invaluable tools in tumor biology, since they reproduce tissue-specific structural features and cell-cell interactions more accurately than conventional 2-D cultures. Multiple Myeloma, which depends on myeloma cell-Bone Marrow microenvironment interactions for development and response to drugs, may particularly benefit from such an approach. An innovative 3-D dynamic culture model based on the use of the RCCS™ Bioreactor was developed to allow long-term culture of myeloma tissue explants. This model was first validated with normal and pathological explants, then applied to tissues from myeloma patients. In all cases, histological examination demonstrated maintenance of viable myeloma cells inside their native microenvironment, with an overall well preserved histo-architecture including bone lamellae and vessels. This system was then successfully applied to evaluate the cytotoxic effects exerted by the proteasome inhibitor Bortezomib not only on myeloma cells but also on angiogenic vessels. Moreover, as surrogate markers of specialized functions expressed by myeloma cells and microenvironment, β2 microglobulin, VEGF and Angiopoietin-2 levels, as well as Matrix Metalloproteases activity, were evaluated in supernatants from 3D cultures and their levels reflected the effects of Bortezomib treatment. Notably, determination of β2 microglobulin levels in supernatants from Bortezomib-treated samples and in patients'sera following Bortezomib-based therapies disclosed an overall concordance in the response to the drug ex vivo and in vivo. Our findings indicate, as a proof of principle, that 3-D, RCCS™ bioreactor-based culture of tissue explants can be exploited for studying myeloma biology and for a pre-clinical approach to patient-targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
39. Heterogeneous synthetic phenotype of cloned scleroderma fibroblasts may be due to aberrant regulation in the synthesis of connective tissues.
- Author
-
Whiteside, Theresa L., Ferrarini, Marina, Hebda, Patricia, and Buckingham, Robert B.
- Published
- 1988
- Full Text
- View/download PDF
40. Hypoxia-inducible transcription factor–1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib
- Author
-
Veschini, Lorenzo, Belloni, Daniela, Foglieni, Chiara, Cangi, Maria Giulia, Ferrarini, Marina, Caligaris-Cappio, Federico, and Ferrero, Elisabetta
- Abstract
Angiogenesis is a complex, orchestrated process that plays a critical role in several conditions and has special relevance in the progression of cancer. Hypoxia is the major stimulus for angiogenesis, and hypoxia-inducible transcription factor–1 alpha (HIF-1α) is its key mediator. We set up a novel in vitro model of HIF-1α up-regulation by treating human umbilical vein endothelial cells (HUVECs) with the hypoxia-mimicking deferoxamine (DFO) and found that this condition was sufficient to promote angiogenesis, like the well-known HUVEC model cultured under low pO2. The proteasome inhibitor bortezomib, which induces strong apoptosis in cancer cells, abrogated proliferation and angiogenesis of HUVECs when used at a high concentration (100 nM), yet promoted both functions at a low dosage (10 nM). This double-edged effect appeared to be mediated by differential effects exerted by the different concentrations of bortezomib on 2 master regulators of tumor-associated angiogenesis, HIF-1α and nuclear factor kappa B (NF-kB). Significantly, when HUVECs were induced to express HIF-1α prior to bortezomib treatment, proliferative and angiogenic responses were abolished, and a greatly enhanced proapoptotic effect was promoted with both concentrations of the drug. These findings indicate that HIF-1α up-regulation may sensitize endothelial cells to the antiangiogenic and proapoptotic effects of bortezomib and might be exploited to target tumor-associated vessels in the course of antiangiogenic therapies.
- Published
- 2007
- Full Text
- View/download PDF
41. Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis
- Author
-
Elisabetta Ferrero, Antonello Villa, Davide Stefanoni, Travis Nemkov, Angelo D’Alessandro, Isak Tengesdal, Daniela Belloni, Raffaella Molteni, Barbara Vergani, Giacomo De Luca, Greta Grassini, Maria Giulia Cangi, Lorenzo Dagna, Claudio Doglioni, Giulio Cavalli, Marina Ferrarini, Ferrero, Elisabetta, Villa, Antonello, Stefanoni, Davide, Nemkov, Travi, D'Alessandro, Angelo, Tengesdal, Isak, Belloni, Daniela, Molteni, Raffaella, Vergani, Barbara, De Luca, Giacomo, Grassini, Greta, Cangi, Maria Giulia, Dagna, Lorenzo, Doglioni, Claudio, Cavalli, Giulio, Ferrarini, Marina, Ferrero, E, Villa, A, Stefanoni, D, Nemkov, T, D'Alessandro, A, Tengesdal, I, Belloni, D, Molteni, R, Vergani, B, De Luca, G, Grassini, G, Giulia Cangi, M, Dagna, L, Doglioni, C, Cavalli, G, and Ferrarini, M
- Subjects
Proto-Oncogene Proteins p21(ras) ,Rheumatology ,3D culture, histiocytosis tissue, KRAS, immunometabolism, macrophage activation ,Macrophages ,Mutation ,MED/06 - ONCOLOGIA MEDICA ,Cytokines ,Gene Expression ,Humans ,Pharmacology (medical) ,Histiocytosis - Published
- 2021
42. 3D Models of Surrogate Multiple Myeloma Bone Marrow Microenvironments : Insights on Disease Pathophysiology and Patient-Specific Response to Drugs
- Author
-
Ferrero, Elisabetta and Ferrarini, Marina
- Subjects
Medical - Abstract
Multiple Myeloma (MM) develops almost exclusively within the Bone Marrow (BM), highlighting the critical role of the microenvironment in conditioning disease progression and resistance to drugs. Indeed, while the therapeutic armamentarium for MM has significantly improved over the past 20 years, the disease remains ultimately incurable. This failure may depend on the high phenotypic and genetic heterogeneity of MM, but also on the paucity and inadequacy of two-dimensional (2D) conventional preclinical models in reproducing MM within the BM. In the present paper, we provide a brief updated overview on MM BM microenvironment. We then discuss newly developed preclinical models mimicking MM/microenvironment interactions, including three-dimensional (3D), gel-based, in vitro models and a novel ex vivo system of isolated tumor and stromal cells cultured in bioreactor. Potential applications of each model, relative to investigation of MM pathogenic mechanisms and prediction of the best drug/combination for each individual patient will be also evaluated.
- Published
- 2022
43. Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease
- Author
-
Mihai G. Netea, Riccardo Biavasco, Lorenzo Dagna, Simone Cenci, Travis Nemkov, Giulio Cavalli, Philippe Maksud, Claudio Doglioni, Gianfranco Distefano, Daniela Cesana, Charles A. Dinarello, Eleonora Cantoni, Anna Kajaste-Rudnitski, Corrado Campochiaro, Simone Cardaci, Daniela Gnani, Isak W. Tengesdal, Julien Haroche, Samuel Zambrano, Alessandro Tomelleri, Giacomo De Luca, Davide Stefanoni, Francesco Piras, Ivan Merelli, Angelo D'Alessandro, Maddalena Panigada, Davide Mazza, Rob J.W. Arts, Jorge Domínguez-Andrés, Alessia Loffreda, Laura Cassina, Raffaella Molteni, Eugenio Montini, Alessandra Boletta, Leo A. B. Joosten, Elisabetta Ferrero, Marina Ferrarini, Biavasco, Riccardo, Molteni, Raffaella, Stefanoni, Davide, Nemkov, Travi, Netea, Mihai G., Domínguez-Andrés, Jorge, Arts, Rob JW, Merelli, Ivan, Mazza, Davide, Zambrano, S, Panigada, Maddalena, Cantoni, Eleonora, Tengesdal, Isak, Maksud, Philippe, Piras, Francesco, De Luca, Giacomo, Cassina, Laura, Distefano, Gianfranco, Loffreda, Alessia, Gnani, Daniela, Doglioni, Claudio, Tomelleri, Alessandro, Campochiaro, Corrado, Joosten, Leo, Dinarello, Charles A, Kajaste-Rudnitski, Anna, Haroche, Julien, Cardaci, Simone, Cenci, Simone, Dagna, Lorenzo, Ferrarini, Marina, Ferrero, Elisabetta, Boletta, Alessandra, D'Alessandro, Angelo, Montini, Eugenio, and Cavalli, Giulio
- Subjects
Proto-Oncogene Proteins B-raf ,Erdheim-Chester Disease ,Myeloid ,medicine.medical_treatment ,Immunology ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Inflammation ,Biochemistry ,Myeloid Neoplasm ,Proinflammatory cytokine ,Epigenesis, Genetic ,Pathogenesis ,medicine ,Humans ,Point Mutation ,Protein kinase B ,Cells, Cultured ,business.industry ,Monocyte ,Macrophages ,Immunity ,Cell Biology ,Hematology ,Oncogenes ,Cytokine ,medicine.anatomical_structure ,Cancer research ,medicine.symptom ,business - Abstract
Trained immunity (TI) is a proinflammatory program induced in monocyte/macrophages upon sensing of specific pathogens and is characterized by immunometabolic and epigenetic changes that enhance cytokine production. Maladaptive activation of TI (ie, in the absence of infection) may result in detrimental inflammation and development of disease; however, the exact role and extent of inappropriate activation of TI in the pathogenesis of human diseases is undetermined. In this study, we uncovered the oncogene-induced, maladaptive induction of TI in the pathogenesis of a human inflammatory myeloid neoplasm (Erdheim-Chester disease, [ECD]), characterized by the BRAFV600E oncogenic mutation in monocyte/macrophages and excess cytokine production. Mechanistically, myeloid cells expressing BRAFV600E exhibit all molecular features of TI: activation of the AKT/mammalian target of rapamycin signaling axis; increased glycolysis, glutaminolysis, and cholesterol synthesis; epigenetic changes on promoters of genes encoding cytokines; and enhanced cytokine production leading to hyperinflammatory responses. In patients with ECD, effective therapeutic strategies combat this maladaptive TI phenotype; in addition, pharmacologic inhibition of immunometabolic changes underlying TI (ie, glycolysis) effectively dampens cytokine production by myeloid cells. This study revealed the deleterious potential of inappropriate activation of TI in the pathogenesis of human inflammatory myeloid neoplasms and the opportunity for inhibition of TI in conditions characterized by maladaptive myeloid-driven inflammation.
- Published
- 2021
44. A Novel Histiocytosis With Synovial and Skin Involvement
- Author
-
Elisabetta Ferrero, Giulio Cavalli, Claudio Doglioni, Lorenzo Dagna, Marina Ferrarini, Giacomo De Luca, Cavalli, Giulio, De Luca, Giacomo, Doglioni, Claudio, Ferrero, Elisabetta, Ferrarini, Marina, and Dagna, Lorenzo
- Subjects
medicine.medical_specialty ,Histiocytosis ,Text mining ,business.industry ,Internal Medicine ,medicine ,MEDLINE ,General Medicine ,business ,medicine.disease ,Dermatology - Published
- 2021
45. The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease
- Author
-
Guido Pacini, Greta Pacini, Alessandro Tomelleri, Lorenzo Dagna, Giacomo De Luca, Giulio Cavalli, Marina Ferrarini, Claudio Doglioni, Pacini, Greta, Cavalli, Giulio, Tomelleri, Alessandro, De Luca, Giacomo, Pacini, Guido, Ferrarini, Marina, Doglioni, Claudio, and Dagna, Lorenzo
- Subjects
0301 basic medicine ,lcsh:Immunologic diseases. Allergy ,Chemokine ,Pathology ,medicine.medical_specialty ,genetic structures ,Immunology ,Disease ,lcsh:RC254-282 ,CCL-18 ,Pathogenesis ,03 medical and health sciences ,Disease severity ,Fibrosis ,Immunology and Allergy ,Medicine ,erdheim-chester disease ,biology ,business.industry ,Brief Report ,fibrosis ,CCL18 ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Histiocytosis ,030104 developmental biology ,Oncology ,Erdheim–Chester disease ,biology.protein ,Erdheim-Chester disease ,ccl-18 ,business ,lcsh:RC581-607 - Abstract
Erdheim-Chester disease (ECD) is a rare histiocytosis, characterized by xanthogranulomatous tissue infiltration by foamy histiocytes. Fibrosis, a histologic hallmark of ECD, is responsible for lesion growth and clinical manifestations. Unraveling molecular fibrotic pathway in ECD would allow the identification of new pharmacologic targets. In this study, we evaluated serum and tissue samples from a large cohort of ECD patients focusing on two major pro-fibrotic mediators, TGF-β1 and chemokine ligand 18 (CCL18). We found a marked increase in CCL18 but not TGF-β1 levels in serum and lesions of ECD patients (p < 0.001), independently of treatment status and consistently over time. Using a linear mathematical model, we also found that elevated CCL18 serum levels correlate with both number and severity of disease localizations. These findings suggest the involvement of CCL18-induced fibrosis in ECD pathogenesis, providing a rationale for exploring CCL18 inhibition as a treatment for progressive fibrosis in ECD.
- Published
- 2018
46. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3d surrogate microenvironment
- Author
-
Stefania Girlanda, Marina Ferrarini, Lorenza Pecciarini, Elisabetta Ferrero, Federico Caligaris-Cappio, Magda Marcatti, Giovanni Tonon, Maurilio Ponzoni, Antonello Villa, Silvia Heltai, Barbara Vergani, Fabio Ciceri, Daniela Belloni, Belloni, D, Heltai, S, Ponzoni, M, Villa, A, Vergani, B, Pecciarini, L, Marcatti, M, Girlanda, S, Tonon, G, Ciceri, F, Caligaris-Cappio, F, Ferrarini, M, Ferrero, E, Belloni, Daniela, Heltai, Silvia, Ponzoni, Maurilio, Villa, Antonello, Vergani, Barbara, Pecciarini, Lorenza, Marcatti, Magda, Girlanda, Stefania, Tonon, Giovanni, Ciceri, Fabio, Caligaris-Cappio, Federico, Ferrarini, Marina, and Ferrero, Elisabetta
- Subjects
0301 basic medicine ,3D model ,medicine.medical_specialty ,Stromal cell ,Cell Survival ,Cell Culture Techniques ,Drug Resistance ,Cell Communication ,Models, Biological ,Article ,Plasma Cell Disorders ,Bortezomib ,03 medical and health sciences ,Bioreactors ,0302 clinical medicine ,Bone Marrow ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Cell Adhesion ,Tumor Microenvironment ,medicine ,Humans ,Multiple myeloma ,Tumor microenvironment ,Hematology ,Chemistry ,Endothelial Cells ,medicine.disease ,Coculture Techniques ,Bone Marrow Microenvironment ,030104 developmental biology ,medicine.anatomical_structure ,Cell culture ,030220 oncology & carcinogenesis ,Cancer research ,Gelatin ,Bone marrow ,Stromal Cells ,Clone (B-cell biology) ,Multiple Myeloma ,medicine.drug - Abstract
Multiple myeloma develops primarily inside the bone marrow microenvironment, that confers pro-survival signals and drug resistance. 3D cultures that reproduce multiple myeloma-bone marrow interactions are needed to fully investigate multiple myeloma pathogenesis and response to drugs. To this purpose, we exploited the 3D Rotary Cell Culture System bioreactor technology for myeloma-bone marrow co-cultures in gelatin scaffolds. The model was validated with myeloma cell lines that, as assessed by histochemical and electron-microscopic analyses, engaged contacts with stromal cells and endothelial cells. Consistently, pro-survival signaling and also cell adhesion-mediated drug resistance were significantly higher in 3D than in 2D parallel co-cultures. The contribution of the VLA-4/VCAM1 pathway to resistance to bortezomib was modeled by the use of VCAM1 transfectants. Soluble factor-mediated drug resistance could be also demonstrated in both 2D and 3D co-cultures. The system was then successfully applied to co-cultures of primary myeloma cells-primary myeloma bone marrow stromal cells from patients and endothelial cells, allowing the development of functional myeloma-stroma interactions and MM cell long-term survival. Significantly, genomic analysis performed in a high-risk myeloma patient demonstrated that culture in bioreactor paralleled the expansion of the clone that ultimately dominated in vivo. Finally, the impact of bortezomib on myeloma cells and on specialized functions of the microenvironment could be evaluated. Our findings indicate that 3D dynamic culture of reconstructed human multiple myeloma microenvironments in bioreactor may represent a useful platform for drug testing and for studying tumor-stroma molecular interactions.
- Published
- 2018
47. 3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target
- Author
-
Antonello Villa, Monica Rodolfo, Elisabetta Ferrero, Lorenzo Dagna, Giulio Cavalli, Marina Ferrarini, Maria Giulia Cangi, Claudio Doglioni, Daniela Belloni, Barbara Vergani, Riccardo Biavasco, Simone Cenci, Villa, Antonello, Belloni, Daniela, Vergani, Barbara, Cenci, Simone, Cavalli, Giulio, Biavasco, Riccardo, Rodolfo, Monica, Cangi, Maria Giulia, Doglioni, Claudio, Dagna, Lorenzo, Ferrero, Elisabetta, Ferrarini, Marina, Villa, A, Belloni, D, Vergani, B, Cenci, S, Cavalli, G, Biavasco, R, Rodolfo, M, Cangi, M, Doglioni, C, Dagna, L, Ferrero, E, and Ferrarini, M
- Subjects
0301 basic medicine ,Erdheim-Chester Disease ,Letter ,medicine.medical_treatment ,Immunology ,General Biochemistry, Genetics and Molecular Biology ,Proinflammatory cytokine ,Tissue Culture Techniques ,03 medical and health sciences ,0302 clinical medicine ,Bioreactors ,Rheumatology ,medicine ,Humans ,Immunology and Allergy ,Molecular Targeted Therapy ,Vemurafenib ,Protein Kinase Inhibitors ,Histiocyte ,030203 arthritis & rheumatology ,Biochemistry, Genetics and Molecular Biology (all) ,CD68 ,business.industry ,Histiocytes ,medicine.disease ,Infliximab ,Histiocytosis ,030104 developmental biology ,Cytokine ,Erdheim–Chester disease ,Cancer research ,business ,medicine.drug - Abstract
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis, characterised by tissue infiltration by foamy CD68+ CD1a− histiocytes.1 The disease has pleomorphic clinical manifestations, including long bones and extraskeletal involvement, and may be life-threatening, particularly when heart and central nervous system are affected.1 ECD histiocytes secrete proinflammatory cytokines2 and carry activating mutations along the RAS-RAF-MEK-ERK protein kinase signalling pathway, most commonly the BRAFV600E oncogenic mutation.3 4 Accordingly, patients with ECD have been treated with cytokine inhibitors, including infliximab,1 ,5 and, more recently, with the BRAFV600E inhibitor vemurafenib.6 The latter, however, induces sustained but partial clinical responses and recurrences on discontinuation,6 underlining the need for more effective therapeutic strategies. To identify the outcomes downstream constitutive ERK phosphorylation in ECD histiocytes and their response to small molecule-based inhibition, we performed three-dimensional (3D) culture of tissues from three BRAFV600E-mutated ECD patients in the RCCS bioreactor7 (and online supplementary methods) in the presence/absence of vemurafenib or infliximab, used as control.### Supplementary data [annrheumdis-2018-214432supp001.pdf] All patient samples maintained production of prototypical cytokines and chemokines2 in bioreactor, thus validating this technology also for ECD; moreover, infliximab, and, to a lesser degree, vemurafenib, significantly decreased cyto-chemokines …
- Published
- 2018
48. Tocilizumab in patients with multisystem Erdheim-Chester disease
- Author
-
B. Guglielmi, Alessandro Tomelleri, Giulio Cavalli, Alvise Berti, Corrado Campochiaro, Roberto Nicoletti, Andrea Panzacchi, Riccardo Biavasco, Lorenzo Dagna, Marina Ferrarini, Berti, Alvise, Cavalli, Giulio, Guglielmi, Barbara, Biavasco, Riccardo, Campochiaro, Corrado, Tomelleri, Alessandro, Nicoletti, Roberto, Panzacchi, Andrea, Ferrarini, Marina, and Dagna, Lorenzo
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,genetic structures ,Immunology ,Erdheim–Chester disease ,Disease ,non-langerhans cell histiocytosis ,Gastroenterology ,ErdheimâChester disease ,03 medical and health sciences ,chemistry.chemical_compound ,Non-Langerhans cell histiocytosis ,tocilizumab ,0302 clinical medicine ,Tocilizumab ,non-Langerhans cell histiocytosi ,Internal medicine ,non-Langerhans cell ,medicine ,Immunology and Allergy ,Prospective cohort study ,Interleukin 6 ,RC254-282 ,medicine.diagnostic_test ,biology ,business.industry ,Brief Report ,interleukin-6 ,erdheim–chester disease ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Magnetic resonance imaging ,RC581-607 ,medicine.disease ,inflammation ,histiocytosis ,Histiocytosis ,030104 developmental biology ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,biology.protein ,Immunologic diseases. Allergy ,business - Abstract
Treatment of ErdheimâChester disease (ECD), a rare non-Langerhans histiocytosis, relies on interferon-α, chemotherapeutic agents such as purine analogs, cytokine-blocking agents and BRAF inhibitors. Since interleukin (IL)-6 levels are elevated in serum and lesions of ECD patients, we evaluated the therapeutic efficacy and safety of IL-6 blockade with tocilizumab. We conducted an open-label, single-arm, phase II, prospective study of tocilizumab in three patients with multisystem ECD and poor tolerance/contraindications to IFN-α. Modifications of symptoms attributed to ECD represented the criteria for evaluation of clinical response. Changes at positron emission tomography scan, computed tomography scan, and magnetic resonance imaging at month 6 represented the main criteria for the evaluation of radiological response. Sustained complete clinical response and partial radiological improvement were observed in two patients, paralleled by modulation of systemic pro-inflammatory mediators. In spite of disease stabilization or improvement at extra-neurological sites, a third patient experienced a radiologic and clinical progression of central nervous system involvement, mirrored by a dramatic increase of circulating IL-6 and related cytokines. These findings indicate that IL-6 inhibition can be effective in ECD, but caution is advisable in patients with neurologic involvement. IL-6 emerges as a central mediator in ECD pathogenesis.
- Published
- 2017
49. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment
- Author
-
Maria Teresa Sabrina Bertilaccio, Federico Caligaris-Cappio, Manfredi Ponente, Paola Brambilla, Giovanni Tonon, Rosa Bernardi, Elisabetta Ferrero, Filippo Martinelli Boneschi, Paolo Ghia, Maurilio Ponzoni, Marina Ferrarini, Andrea Brendolan, Elisa Lenti, Elisa Ten Hacken, Lydia Scarfò, Cristina Scielzo, Daniela Belloni, Roberta Valsecchi, Nadia Coltella, Valsecchi, Roberta, Coltella, Nadia, Belloni, Daniela, Ponente, Manfredi, Ten Hacken, Elisa, Scielzo, Cristina, Scarfò, Lydia, Bertilaccio, Maria Teresa Sabrina, Brambilla, Paola, Lenti, Elisa, Boneschi, Filippo Martinelli, Brendolan, Andrea, Ferrero, Elisabetta, Ferrarini, Marina, Ghia, PAOLO PROSPERO, Tonon, Giovanni, Ponzoni, Maurilio, CALIGARIS CAPPIO, Federico, and Bernardi, Rosa
- Subjects
0301 basic medicine ,Stromal cell ,Chronic lymphocytic leukemia ,Immunology ,Mice, Transgenic ,Cell Communication ,Biology ,Biochemistry ,03 medical and health sciences ,Chemokine receptor ,Mice ,0302 clinical medicine ,HEK293 Cell ,immune system diseases ,Bone Marrow ,hemic and lymphatic diseases ,medicine ,Cell Adhesion ,Tumor Microenvironment ,Animals ,Humans ,Cell adhesion ,neoplasms ,Tumor microenvironment ,Lymphoid Neoplasia ,Cell adhesion molecule ,Animal ,Gene Expression Regulation, Leukemic ,Stromal Cell ,Hematology ,Cell Biology ,medicine.disease ,Hypoxia-Inducible Factor 1, alpha Subunit ,Leukemia, Lymphocytic, Chronic, B-Cell ,Cell biology ,Mice, Inbred C57BL ,Leukemia ,Chemotaxis, Leukocyte ,030104 developmental biology ,medicine.anatomical_structure ,HEK293 Cells ,030220 oncology & carcinogenesis ,Bone marrow ,Stromal Cells ,Spleen ,Human - Abstract
Hypoxia-inducible transcription factors (HIFs) regulate a wide array of adaptive responses to hypoxia and are often activated in solid tumors and hematologic malignancies due to intratumoral hypoxia and emerging new layers of regulation. We found that in chronic lymphocytic leukemia (CLL), HIF-1α is a novel regulator of the interaction of CLL cells with protective leukemia microenvironments and, in turn, is regulated by this interaction in a positive feedback loop that promotes leukemia survival and propagation. Through unbiased microarray analysis, we found that in CLL cells, HIF-1α regulates the expression of important chemokine receptors and cell adhesion molecules that control the interaction of leukemic cells with bone marrow and spleen microenvironments. Inactivation of HIF-1α impairs chemotaxis and cell adhesion to stroma, reduces bone marrow and spleen colonization in xenograft and allograft CLL mouse models, and prolongs survival in mice. Of interest, we found that in CLL cells, HIF-1α is transcriptionally regulated after coculture with stromal cells. Furthermore, HIF-1α messenger RNA levels vary significantly within CLL patients and correlate with the expression of HIF-1α target genes, including CXCR4, thus further emphasizing the relevance of HIF-1α expression to CLL pathogenesis.
- Published
- 2016
50. ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies.
- Author
-
Botrugno OA, Bianchessi S, Zambroni D, Frenquelli M, Belloni D, Bongiovanni L, Girlanda S, Di Terlizzi S, Ferrarini M, Ferrero E, Ponzoni M, Marcatti M, and Tonon G
- Subjects
- Animals, Apoptosis, Ataxia Telangiectasia Mutated Proteins genetics, Ataxia Telangiectasia Mutated Proteins metabolism, Cell Line, Tumor, Cell Survival, DNA Damage, DNA Repair, Humans, Melphalan pharmacology, Multiple Myeloma drug therapy, Multiple Myeloma genetics
- Abstract
Therapeutic strategies designed to tinker with cancer cell DNA damage response have led to the widespread use of PARP inhibitors for BRCA1/2-mutated cancers. In the haematological cancer multiple myeloma, we sought to identify analogous synthetic lethality mechanisms that could be leveraged upon established cancer treatments. The combination of ATR inhibition using the compound VX-970 with a drug eliciting interstrand cross-links, melphalan, was tested in in vitro, ex vivo, and most notably in vivo models. Cell proliferation, induction of apoptosis, tumor growth and animal survival were assessed. The combination of ATM inhibition with a drug triggering double strand breaks, doxorucibin, was also probed. We found that ATR inhibition is strongly synergistic with melphalan, even in resistant cells. The combination was dramatically effective in targeting myeloma primary patient cells and cell lines reducing cell proliferation and inducing apoptosis. The combination therapy significantly reduced tumor burden and prolonged survival in animal models. Conversely, ATM inhibition only marginally impacted on myeloma cell survival, even in combination with doxorucibin at high doses. These results indicate that myeloma cells extensively rely on ATR, but not on ATM, for DNA repair. Our findings posit that adding an ATR inhibitor such as VX-970 to established therapeutic regimens may provide a remarkably broad benefit to myeloma patients.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.